Coherus Biosciences | CHRS - Pre Tax Profit


Coherus Biosciences reported $-46.35M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amarin USD -852K 7.26M Dec/2025
Amgen USD 2.08B 570M Mar/2026
Baxter International USD 362M 368M Jun/2026
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Eli Lilly USD 8.85B 583.8M Mar/2026
Fujifilm JPY 104.44B 4.16B Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
Merck USD -3.53B 6.95B Mar/2026
Myriad Genetics USD 4.6M 3.4M Dec/2025
Pacira USD 5M 4.43M Mar/2026
Perrigo USD 105.4M 513.9M Jun/2026
Pfizer USD -653M 5.84B Jun/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Teva Pharmaceutical Industries USD -455M 1.21B Jun/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026
Xencor USD -21.92M 106.72M Jun/2026
Zoetis USD 758M 3M Mar/2026